David N. Assis

4.4k total citations · 2 hit papers
60 papers, 2.0k citations indexed

About

David N. Assis is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, David N. Assis has authored 60 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Hepatology, 28 papers in Epidemiology and 21 papers in Surgery. Recurrent topics in David N. Assis's work include Liver Diseases and Immunity (37 papers), Liver Disease Diagnosis and Treatment (26 papers) and Pediatric Hepatobiliary Diseases and Treatments (12 papers). David N. Assis is often cited by papers focused on Liver Diseases and Immunity (37 papers), Liver Disease Diagnosis and Treatment (26 papers) and Pediatric Hepatobiliary Diseases and Treatments (12 papers). David N. Assis collaborates with scholars based in United States, Canada and Germany. David N. Assis's co-authors include James L. Boyer, Nisanne S. Ghonem, Cara L. Mack, Simon C. Ling, Marlyn J. Mayo, Mouaz Alsawas, M. Hassan Murad, Albert J. Czaja, Michael P. Manns and David Adams and has published in prestigious journals such as Gastroenterology, Hepatology and Journal of Hepatology.

In The Last Decade

David N. Assis

56 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases

2019 513 citations Cara L. Mack, David N. Assis et al. Hepatology profile →
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma

2022 152 citations Christopher L. Bowlus, Annika Bergquist et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David N. Assis United States	22	1.2k	1.1k	704	314	290	60	2.0k
Nora Cazzagon Italy	24	1.6k 1.3×	1.7k 1.6×	641 0.9×	111 0.4×	216 0.7×	69	2.2k
Takanori Ito Japan	23	900 0.7×	983 0.9×	296 0.4×	199 0.6×	138 0.5×	147	1.8k
Yoichiro Uchida Japan	24	606 0.5×	273 0.3×	817 1.2×	188 0.6×	201 0.7×	94	1.6k
Ricky H. Bhogal United Kingdom	19	770 0.6×	372 0.4×	887 1.3×	135 0.4×	113 0.4×	75	1.4k
Naoko Kamo Japan	23	628 0.5×	419 0.4×	713 1.0×	357 1.1×	148 0.5×	69	1.8k
Yoshio Tokumoto Japan	22	840 0.7×	1.1k 1.1×	219 0.3×	107 0.3×	81 0.3×	124	1.6k
Erwin Biecker Germany	18	671 0.5×	577 0.5×	539 0.8×	244 0.8×	245 0.8×	45	1.3k
Franco Sasso Italy	11	608 0.5×	1.4k 1.4×	195 0.3×	338 1.1×	78 0.3×	20	2.1k
Bao Luo United States	22	784 0.6×	286 0.3×	605 0.9×	60 0.2×	357 1.2×	31	1.5k
Konstantin Kazankov Denmark	19	762 0.6×	1.4k 1.3×	343 0.5×	78 0.2×	55 0.2×	43	1.9k

Countries citing papers authored by David N. Assis

Since Specialization

Citations

This map shows the geographic impact of David N. Assis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David N. Assis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David N. Assis more than expected).

Fields of papers citing papers by David N. Assis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David N. Assis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David N. Assis. The network helps show where David N. Assis may publish in the future.

Co-authorship network of co-authors of David N. Assis

This figure shows the co-authorship network connecting the top 25 collaborators of David N. Assis. A scholar is included among the top collaborators of David N. Assis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David N. Assis. David N. Assis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Valenti, Vítor Engrácia, Rodrigo Daminello Raimundo, Jacopo Crippa, et al.. (2025). The impact of exercise on cardiovascular parameters in postmenopausal women: A narrative review. Maturitas. 201. 108688–108688.

Kochhar, Sonali, David N. Assis, Cara L. Mack, et al.. (2024). Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine. 42(7). 1812–1825. 2 indexed citations

Hussain, Nasir, Christopher Ma, Gideon M. Hirschfield, et al.. (2024). Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis. BMJ Open. 14(6). e080143–e080143. 3 indexed citations

Engel, Bastian, David N. Assis, Mamatha Bhat, et al.. (2024). Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024. JHEP Reports. 7(2). 101265–101265. 1 indexed citations

Snijders, Romée J.A.L.M., David N. Assis, Ye Htun Oo, et al.. (2023). Research gaps and opportunities in autoimmune hepatitis—Results of the international autoimmune hepatitis group research workshop 2022. Liver International. 43(7). 1375–1384. 10 indexed citations

Assis, David N. & Christopher L. Bowlus. (2023). Recent Advances in the Management of Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology. 21(8). 2065–2075. 27 indexed citations

Rabiee, Anahita, Scott Roberts, Yanhong Deng, et al.. (2022). Mindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitis. JHEP Reports. 4(5). 100450–100450. 8 indexed citations

Guercio, Brendan J., Gopa Iyer, Wajih Zaheer Kidwai, et al.. (2021). Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. Case Reports in Oncology. 14(1). 430–438. 14 indexed citations

Ghonem, Nisanne S., et al.. (2020). Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol. Clinical Pharmacology & Therapeutics. 108(6). 1213–1223. 41 indexed citations

10.

Kim, Hannah P., Sarah R. Lieber, Andrew M. Moon, et al.. (2020). A Systematic Review of Patient‐Reported Outcomes in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Hepatology Communications. 4(10). 1502–1515. 13 indexed citations

11.

Soroka, Carol J., David N. Assis, & James L. Boyer. (2019). Patient-Derived Organoids from Human Bile: An In Vitro Method to Study Cholangiopathies. Methods in molecular biology. 1981. 363–372. 7 indexed citations

12.

Hakim, Aaron, Xuchen Zhang, Elif A Oral, et al.. (2019). Clinical utility of genomic analysis in adults with idiopathic liver disease. Journal of Hepatology. 70(6). 1214–1221. 49 indexed citations

13.

Assis, David N. & Dominique Debray. (2017). Gallbladder and bile duct disease in Cystic Fibrosis. Journal of Cystic Fibrosis. 16. S62–S69. 42 indexed citations

14.

Kim, Bong‐Sung, Christian Stoppe, Gerrit Grieb, et al.. (2016). The clinical significance of the MIF homolog d-dopachrome tautomerase (MIF-2) and its circulating receptor (sCD74) in burn. Burns. 42(6). 1265–1276. 17 indexed citations

15.

Beinhardt, S., et al.. (2015). Poster Session 1: Autoimmune Liver Disease. Hepatology. 62(S1). 363A–370A. 1 indexed citations

16.

Assis, David N. & Steven D. Freedman. (2015). Gastrointestinal Disorders in Cystic Fibrosis. Clinics in Chest Medicine. 37(1). 109–118. 32 indexed citations

17.

Assis, David N., Lin Leng, Xin Du, et al.. (2013). The Role of Macrophage Migration Inhibitory Factor in Autoimmune Liver Disease. Hepatology. 59(2). 580–591. 89 indexed citations

18.

Assis, David N., Christine A. Caldwell, Antonios Arvelakis, et al.. (2011). Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation. Transplantation Proceedings. 43(3). 905–908. 17 indexed citations

19.

Rossi, Simona, David N. Assis, Jocelyn Andrel, et al.. (2008). Use of Over-the-Counter Analgesics in Patients with Chronic Liver Disease. Drug Safety. 31(3). 261–270. 38 indexed citations

20.

Cinalli, Giuseppe, et al.. (2001). Treatment of post-haemorrhage ventricular dilatation with an Ommaya's reservoir: management and outcome of 64 preterm infants. Child s Nervous System. 17(6). 334–340. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact